Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in JAMA Oncol Retrieve available abstracts of 20 articles: HTML format Text format

Single Articles

December 2018
1. TOI Y, Sugawara S, Sugisaka J, Ono H, et al
   Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
   JAMA Oncol. 2018 Dec 27. pii: 2718925. doi: 10.1001/jamaoncol.2018.5860.
   PubMed     Text format     Abstract available
   
   
   
2. CRISS SD, Mooradian MJ, Sheehan DF, Zubiri L, et al
   Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
   JAMA Oncol. 2018 Dec 13. pii: 2718006. doi: 10.1001/jamaoncol.2018.5449.
   PubMed     Text format     Abstract available
   
   
   
3. SALEM A, Mistry H, Hatton M, Locke I, et al
   Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
   JAMA Oncol. 2018 Dec 6:e185335. doi: 10.1001/jamaoncol.2018.5335.
   PubMed     Text format     Abstract available
   
   
   
4. WEST HJ
   Moving Beyond Limited and Extensive Staging of Small Cell Lung Cancer.
   JAMA Oncol. 2018 Dec 6. pii: 2717231. doi: 10.1001/jamaoncol.2018.5187.
   PubMed     Text format    
   
   
   November 2018
5. CHEN XZ
   Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.
   JAMA Oncol. 2018 Nov 29. pii: 2716809. doi: 10.1001/jamaoncol.2018.5526.
   PubMed     Text format    
   
   
   
6. SLOAN L, Romo CG, Hales RK
   Hemifacial Hyperhidrosis in a Patient With an Apical Non-Small Cell Lung Cancer.
   JAMA Oncol. 2018 Nov 15. pii: 2713851. doi: 10.1001/jamaoncol.2018.4597.
   PubMed     Text format    
   
   
   October 2018
7. EZE C, Kasmann L, Manapov F
   Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer.
   JAMA Oncol. 2018 Oct 25. pii: 2707226. doi: 10.1001/jamaoncol.2018.4833.
   PubMed     Text format    
   
   
   
8. GYAWALI B, West HJ
   Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer-Either, Both, or Neither?
   JAMA Oncol. 2018 Oct 11. pii: 2705603. doi: 10.1001/jamaoncol.2018.4304.
   PubMed     Text format    
   
   
   
9. AGGARWAL C, Thompson JC, Black TA, Katz SI, et al
   Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
   JAMA Oncol. 2018 Oct 11. pii: 2705609. doi: 10.1001/jamaoncol.2018.4305.
   PubMed     Text format     Abstract available
   
   
   
10. BOOZALIS E, Kwatra SG, Marrone KA
    Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 4. pii: 2704206. doi: 10.1001/jamaoncol.2018.4485.
    PubMed     Text format    
    
    
    September 2018
11. TUMINELLO S, Schwartz RM, Liu B, Mhango G, et al
    Opioid Use After Open Resection or Video-Assisted Thoracoscopic Surgery for Early-Stage Lung Cancer.
    JAMA Oncol. 2018 Sep 24. pii: 2703444. doi: 10.1001/jamaoncol.2018.4387.
    PubMed     Text format    
    
    
    
12. FERRARA R, Mezquita L, Texier M, Lahmar J, et al
    Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    JAMA Oncol. 2018 Sep 6. pii: 2698845. doi: 10.1001/jamaoncol.2018.3676.
    PubMed     Text format     Abstract available
    
    
    August 2018
13. GRIDELLI C, de Castro Carpeno J, Dingemans AC, Griesinger F, et al
    Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
    JAMA Oncol. 2018 Aug 30:e183486. doi: 10.1001/jamaoncol.2018.3486.
    PubMed     Text format     Abstract available
    
    
    
14. HAN B, Li K, Wang Q, Zhang L, et al
    Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2018 Aug 9. pii: 2696341. doi: 10.1001/jamaoncol.2018.3039.
    PubMed     Text format     Abstract available
    
    
    
15. ALCORN SR, Miller DB, Hales RK
    Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer.
    JAMA Oncol. 2018 Aug 2. pii: 2694876. doi: 10.1001/jamaoncol.2018.3261.
    PubMed     Text format    
    
    
    
16. PASQUINELLI MM, Kovitz KL, Koshy M, Menchaca MG, et al
    Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial.
    JAMA Oncol. 2018 Aug 2. pii: 2694875. doi: 10.1001/jamaoncol.2018.2823.
    PubMed     Text format    
    
    
    
17. CHUN SG, Pezzi TA, Schwartz DL
    Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2018 Aug 2. pii: 2694877. doi: 10.1001/jamaoncol.2018.3292.
    PubMed     Text format    
    
    
    
18. OXNARD GR, Hu Y, Mileham KF, Husain H, et al
    Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
    JAMA Oncol. 2018 Aug 2. pii: 2694879. doi: 10.1001/jamaoncol.2018.2969.
    PubMed     Text format     Abstract available
    
    
    July 2018
19. GUIDA F, Sun N, Bantis LE, Muller DC, et al
    Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
    JAMA Oncol. 2018 Jul 12:e182078. doi: 10.1001/jamaoncol.2018.2078.
    PubMed     Text format     Abstract available
    
    
    June 2018
20. GANDARA DR, Riess JW, Lara PN Jr
    In Search of an Oncogene Driver for Squamous Lung Cancer.
    JAMA Oncol. 2018 Jun 14. pii: 2684629. doi: 10.1001/jamaoncol.2018.0774.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: